Dabigatran etexilate is under clinical development by Hong Kong WD Pharmaceutical and currently in Phase I for Deep Vein Thrombosis (DVT). According to GlobalData, Phase I drugs for Deep Vein ...

In a large study, dabigatran was as effective as low-dose enoxaparin for preventing VTE after knee replacement. Coumarin-derived drugs such as warfarin have been the mainstay of oral anticoagulant ...

Dabigatran Etexilate is a medicine known as an anticoagulant or blood thinner. It helps prevent and treat blood clots. It is used to reduce the risk of stroke and heart attack. It prevents and treats ...

From the Louisiana State University School of Medicine, New Orleans (R.N.); Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA (M.D.E., M.C ...

Dabigatran has been reimbursed by the Taiwan NHI program for stroke prevention in AF patients with an estimated glomerular filtration rate ≥30 mL/min per 1.73 m 2 since June 1, 2012. Although ...

Current guidelines have no recommendations on the utilization of novel oral anticoagulants, such as dabigatran, for the prevention of thromboembolic events in patients with mechanical heart valves.